InterMune Offers Added Pirfenidone Data in Idiopathic Pulmonary Fibrosis, Says Endpoint Was Met with Statistical Significance in Capacity 2
May 20, 2014 at 17:03 PM EDT
InterMune, Inc. (NASDAQ: ITMN) today announced that results of analyses of pooled data from the ASCEND trial and the two previous ...
